J 2023

European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM<i> Candida</i> III study

ARENDRUP, Maiken Cavling, Sevtap ARIKAN-AKDAGLI, Karin Meinike JORGENSEN, Aleksandra BARAC, Jorg STEINMANN et. al.

Základní údaje

Originální název

European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM<i> Candida</i> III study

Autoři

ARENDRUP, Maiken Cavling, Sevtap ARIKAN-AKDAGLI, Karin Meinike JORGENSEN, Aleksandra BARAC, Jorg STEINMANN, Cristina TOSCANO, Valentina Arsic ARSENIJEVIC, Assunta SARTOR, Cornelia LASS-FLOERL, Axel HAMPRECHT, Tadeja MATOS, Benedict R S ROGERS, Inmaculada QUILES, Jochem BUIL, Volkan OZENCI, Robert KRAUSE, Matteo BASSETTI, Laura LOUGHLIN, Blandine DENIS, Anna GRANCINI, P Lewis WHITE, Katrien LAGROU, Birgit WILLINGER, Riina RAUTEMAA-RICHARDSON, Petr HAMAL, Beyza ENER, Tugce UNALAN-ALTINTOP, Ebru EVREN, Suleyha HILMIOGLU-POLAT, Yasemin OZ, Ozlem Koyuncu OZYURT, Faruk AYDIN, Filip RŮŽIČKA (203 Česká republika, domácí), Eelco F J MEIJER, Jean Pierre GANGNEUX, Deborah E A LOCKHART, Nina KHANNA, Clare LOGAN, Ulrike SCHARMANN, Guillaume DESOUBEAUX, Emmanuel ROILIDES, Alida Fe TALENTO, van Dijk KARIN, Philipp KOEHLER, Jon SALMANTON-GARCIA, Oliver A CORNELY a Martin HOENIGL

Vydání

JOURNAL OF INFECTION, LONDON, W B SAUNDERS CO LTD, 2023, 0163-4453

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 28.200 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133411

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

001103177000001

Klíčová slova anglicky

Candida; C. parapsilosis; Fluconazole resistance; Echinocandin resistance; Fks1; EUCAST

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 2. 2. 2024 10:23, Mgr. Tereza Miškechová

Anotace

V originále

The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candi-daemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/ country determined by population size) included-10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin re-sistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25-33%) while Italy and Turkey had the highest C. parapsilosis proportions (24-26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).